Emmanuel Mongodin

Assistant Professor
CORE A: Administration and Planning (RP3 Administration)
Research Project 3: Exploring Tobacco Microbial Constituents and the Oral Microbiome of Tobacco Users (Co-Principal Investigator)

Dr. Emmanuel F. Mongodin is currently an Assistant Professor the Department of Microbiology and Immunology at the University of Maryland School of Medicine (SOM) and the Institute for Genome Sciences (IGS). Dr. Mongodin received his Ph.D from the University of Reims-Champagne Ardenne in France in 2000, where he studied the interactions between Staphyloccus aureus and the human respiratory epithelium. He then completed a postdoctoral training in the laboratory of Dr. Gordon Archer (VCU, Richmond, VA) carrying out research focused on the mechanisms of acquisition of antibiotic resistance in Staphylococcus aureus and epidermidis, using both comparative genomics and transcriptomics (expression profiling using microarrays) approaches. In 2002, Dr. Mongodin joined The Institute for Genome Research (TIGR; Rockville, MD) as a Staff Scientist and later the J. Craig Venter Institute, where he participated in and led numerous genome-sequencing projects such as Borrelia sp., Campylobacter sp., Listeria monocytogenes, Staphylococcus aureus and Staphylococcus epidermidis, and developed a strong expertise in genomics, comparative genomics as well as metagenomics.

Dr. Mongodin's primary research interests focus on the application of microbial genomics, comparative genomics and metagenomic approaches to the study of host-bacteria interactions and the microbial populations colonizing the human body. His current research projects include 1) the role of the human microbiome associated with S. aureus colonization of the anterior nares, and more specifically the effects of decolonization regimens ; 2) the study of the oral microbiome and its role in oral diseases such as periodontal and endodontic disease ; 3) the role of the bacterial communities associated with cigarettes, smokeless tobacco products, new and emerging nicotine delivery products, and their effect on the oral microbiome of tobacco users.